RICHMOND, British Columbia, March 18, 2025 (GLOBE NEWSWIRE) -- bioLytical Laboratories Inc. (“bioLytical”), a global leader in rapid infectious disease diagnostics, announces the launch of its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia. Now included in the Australian Register of Therapeutic Goods (ARTG number: 482706), this dual HIV-syphilis test provides results in just 60 seconds, helping healthcare professionals diagnose HIV and syphilis efficiently and connect patients to care faster..

里士满，不列颠哥伦比亚省，2025年3月18日（环球新闻社）——快速传染病诊断领域的全球领导者bioLytical Laboratories Inc.（“bioLytical”）宣布在澳大利亚推出其INSTI® Multiplex HIV-1/2梅毒抗体检测产品。该HIV和梅毒双重检测产品现已列入澳大利亚治疗用品注册处（ARTG编号：482706），可在短短60秒内提供结果，帮助医疗专业人员高效诊断HIV和梅毒，并更快地将患者与医疗服务对接。

“Access to fast, reliable rapid testing is critical to eliminating infectious diseases as public health threats,” said Robert Mackie, CEO of bioLytical. “We’re proud to bring our dual HIV-syphilis test to support Australia’s public health initiatives. We know that expanding access to testing enables faster diagnoses and plays a key role in reducing transmission and improving treatment outcomes.

“获取快速、可靠的快速检测对于消除传染病作为公共卫生威胁至关重要，”bioLytical首席执行官罗伯特·麦基表示。“我们很自豪能够带来我们的双重HIV-梅毒测试，以支持澳大利亚的公共卫生计划。我们知道，扩大检测的可及性能够实现更快的诊断，并在减少传播和改善治疗效果方面发挥关键作用。”

We remain committed to offering a vital tool for healthcare professionals in Australia and worldwide.”.

我们仍然致力于为澳大利亚乃至全球的医疗专业人员提供重要的工具。

With its rapid results and ease of use, the INSTI® Multiplex Test is a valuable resource for clinics, hospitals, and outreach programs, particularly in communities with limited access to laboratory testing. By increasing access to early and reliable detection, the test aligns with Australia's national STI screening and public health strategies..

由于其快速出结果和使用方便，INSTI®多重检测是诊所、医院和外展项目的宝贵资源，特别是在难以获得实验室检测的社区。通过增加早期和可靠检测的机会，该检测与澳大利亚的国家性传播感染筛查和公共卫生战略保持一致。

Why Rapid HIV and Syphilis Testing Matters

为什么快速艾滋病毒和梅毒检测很重要

HIV and syphilis continue to pose significant public health challenges in Australia:

HIV 和梅毒继续在澳大利亚构成重大的公共卫生挑战：

722 new HIV diagnoses were reported nationally in 2023

2023年全国报告了722例新的艾滋病病毒诊断病例

, up from 553 in 2022, though overall trends remain lower than pre-pandemic levels.

，高于2022年的553，但总体趋势仍低于疫情前的水平。

An estimated 30,000 people are currently living with HIV in Australia

据估计，目前澳大利亚有30,000人感染了艾滋病毒。

, underscoring the importance of accessible testing.

，强调了可访问性测试的重要性。

Syphilis infections were recorded in almost every region in 2023

2023年，几乎所有地区都记录了梅毒感染病例。

, reinforcing the need for increased screening.

，进一步加强了增加筛查的必要性。

Both HIV and syphilis can be asymptomatic in early stages,

艾滋病毒和梅毒在早期阶段可能都没有症状，

making regular testing essential to prevent further transmission.

进行定期测试对于防止进一步传播至关重要。

The INSTI® Multiplex HIV-1/2 Syphilis Antibody Test is already used in other global markets, such as Canada and across Europe, with Health Canada authorization and its CE Mark, respectively. This contributes to improved testing accessibility and early diagnosis initiatives. Expanding availability in Australia helps more individuals learn their status quickly and access care..

INSTI® Multiplex HIV-1/2 梅毒抗体检测已经在其他全球市场中使用，例如加拿大和整个欧洲，分别获得了加拿大卫生部的授权和CE标志。这有助于提高检测的可及性和早期诊断工作的推进。在澳大利亚扩大供应可以帮助更多人快速了解自己的状况并获得治疗。

Fast, Reliable, and Easy to Use

快速、可靠且易于使用

The INSTI® Multiplex HIV-1/2 Syphilis Antibody Test requires just a single drop of fingerstick blood. It provides highly accurate results in 60 seconds – helping healthcare professionals reach more people and connect them to treatment and care while working to reduce onward infections.

INSTI® 多重 HIV-1/2 梅毒抗体测试只需一滴指尖血。它能在60秒内提供高度准确的结果——帮助医疗专业人员接触到更多人群，并将他们与治疗和护理联系起来，同时努力减少后续感染。

Key Benefits:

主要好处：

Ultra-fast: Results in just 60 seconds—the fastest dual HIV/syphilis rapid test available.

超快速：仅需60秒即可出结果——市面上最快的双重HIV/梅毒快速检测。

Highly accurate: Clinically validated with industry-leading sensitivity and specificity.

高度准确：经过临床验证，具有行业领先的灵敏度和特异性。

Portable and shelf-stable: Ideal for both clinical and outreach settings.

便携且货架稳定：非常适合临床和外展环境。

Supports immediate patient engagement: Ensures individuals receive care without delay.

支持即时患者参与：确保个人及时获得护理。

Where to Access the Test

在何处进行测试

The INSTI® Multiplex HIV-1/2 Syphilis Antibody Test is now available for professional use across Australia. Healthcare providers can contact bioLytical or authorized distributors for purchasing details.

INSTI® Multiplex HIV-1/2 梅毒抗体检测现在在澳大利亚各地可供专业使用。医疗保健提供者可以联系 bioLytical 或授权分销商获取购买详情。

A New Era in Infectious Disease Screening

传染病筛查的新时代

“With rapid results for both HIV and syphilis, this test helps healthcare professionals diagnose infections faster and connect patients to care sooner,” said David Weaver, VP of Commercial, bioLytical. “By simplifying the screening process and reducing delays, we are making reliable and accurate testing more accessible and improving health outcomes across Australia.”.

“通过快速得出 HIV 和梅毒的结果，该测试有助于医疗专业人员更快地诊断感染，并更快地将患者与治疗联系起来，” bioLytical 商业副总裁 David Weaver 表示。“通过简化筛查流程并减少延迟，我们正在让可靠且准确的检测变得更易获取，从而改善整个澳大利亚的健康结果。”

bioLytical’s Commitment to Public Health

bioLytical对公共卫生的承诺

bioLytical manufactures the INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in its MDSAP/ISO 13485-certified facility, ensuring the highest quality standards. As a global leader in rapid infectious disease diagnostics, bioLytical operates in over 70 countries and is dedicated to expanding access to fast, accurate, and reliable testing solutions worldwide..

bioLytical在其获得MDSAP/ISO 13485认证的设施中生产INSTI® Multiplex HIV-1/2梅毒抗体测试，确保最高质量标准。作为快速传染病诊断的全球领导者，bioLytical在超过70个国家开展业务，并致力于在全球范围内扩大快速、准确和可靠的检测解决方案的可及性。

About bioLytical Laboratories Inc.

关于bioLytical Laboratories Inc.

bioLytical Laboratories Inc. is a privately held Canadian company focused on researching, developing, and commercializing rapid diagnostic tests. Utilizing its proprietary INSTI® technology platform and lateral flow line, iStatis, bioLytical delivers real-time, highly accurate results that empower medical professionals, patients, and public health organizations worldwide.

bioLytical Laboratories Inc. 是一家私营的加拿大公司，专注于快速诊断测试的研究、开发和商业化。通过利用其专有的INSTI®技术平台和横向流动线iStatis，bioLytical提供实时、高度准确的结果，助力全球的医疗专业人员、患者和公共卫生组织。

As a global leader in rapid diagnostics, bioLytical continues to build solutions that improve global health outcomes..

作为快速诊断领域的全球领导者，bioLytical继续构建改善全球健康结果的解决方案。